Home > Boards > US Listed > Biotechs > Compugen (CGEN)

Biotech News: Investor Alert for Compugen Ltd.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 98
Posts 23,197
Boards Moderated 2
Alias Born 02/07/04
160x600 placeholder
Compugen Reports First Quarter 2019 Results PR Newswire (US) - 5/20/2019 7:05:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/20/2019 7:01:27 AM
Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid ... PR Newswire (US) - 5/20/2019 7:00:00 AM
Compugen First Quarter 2019 Conference Call Scheduled for Monday, May 20, 2019 at 8:30 AM ET PR Newswire (US) - 5/6/2019 7:00:00 AM
Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting PR Newswire (US) - 4/3/2019 7:00:00 AM
Chinese Regulatory Authority [NMPA] Approves IND Application of Oramed's Oral Insulin Capsules PR Newswire (US) - 3/26/2019 8:40:00 AM
Compugen Announces Purchase of Company Shares by its Board of Directors and Members of Management PR Newswire (US) - 3/26/2019 7:00:00 AM
Annual and Transition Report (foreign Private Issuer) (20-f) Edgar (US Regulatory) - 3/21/2019 6:43:17 AM
Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate PR Newswire (US) - 3/12/2019 7:46:00 AM
Compugen to Present at the Cowen and Company 39th Annual Health Care Conference PR Newswire (US) - 3/5/2019 7:00:00 AM
Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-Oncology Symposium PR Newswire (US) - 3/1/2019 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 2/26/2019 6:07:47 AM
Compugen Reports Fourth Quarter and Full Year 2018 Results and Announces Corporate Restructuring to Streamline Operations PR Newswire (US) - 2/26/2019 2:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/14/2019 11:35:18 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2019 8:42:00 AM
Compugen Fourth Quarter and Full Year 2018 Conference Call Scheduled for Tuesday, February 26, 2019 at 8:30 AM ET PR Newswire (US) - 2/14/2019 7:00:00 AM
Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for C... PR Newswire (US) - 1/22/2019 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/17/2019 11:51:42 AM
Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium PR Newswire (US) - 1/14/2019 7:00:00 AM
Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 12/4/2018 4:28:34 PM
Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy PR Newswire (US) - 11/13/2018 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 11/7/2018 7:02:14 AM
Compugen Reports Third Quarter 2018 Results PR Newswire (US) - 11/7/2018 7:00:00 AM
Compugen Third Quarter 2018 Conference Call Scheduled for Wednesday, November 7, 2018 at 8:30 AM ET PR Newswire (US) - 10/24/2018 7:15:00 AM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 10/16/2018 11:04:11 AM
midastouch017   Thursday, 04/05/07 10:07:11 AM
Re: None
Post # of 167 
Biotech News: Investor Alert for Compugen Ltd.
via COMTEX

April 5, 2007

Apr 05, 2007 (M2 PRESSWIRE via COMTEX News Network) --

Proteins and genes are Compugen's favorite things. The company has been developing technologies to improve the discovery processes of genomics and proteomics. LEADS, its bioinformatics platform, helps accelerate the analysis of genomic and protein data. Now Compugen is incorporating its technology and various research methods to expedite its own drug discovery efforts. The company has a pipeline of early-stage therapeutic protein candidates discovered by the company. It also has licensed several others to customers and collaborators such as Abbott Labs, Pfizer, and Novartis.

Shares were down 6% expanding test pact with Biosite.

BellwetherReport.com is a leading online research firm for international investors looking to get an edge over their portfolio. Investors seeking the most up to date information on Compugen Ltd. are invited to sign up for a free complimentary subscription to www.bellwetherreport.com. No credit card needed!

Israeli drug developer Compugen Ltd. said Wednesday it signed a second agreement with medical test maker Biosite Inc. to develop and market products that help test for and diagnose diseases.

Financial terms were not disclosed.

San Diego-based Biosite will now have access to a greater number of potential diagnostic biomarkers as well as Compugen's inventory of immunoassay biomarkers. An immunoassay is a biochemical test that measures the level of a substance in blood or urine by looking at how an antibody reacts to a certain molecule.

Detecting biomarkers specific to a disease -- such as breast cancer -- can help doctors identify, diagnose and treat individuals suffering from illness as well as people who may be at risk but do not yet show symptoms.

The deal also covers new diagnostic areas, including cardiovascular and oncology.

As in the previous agreement, Compugen will receive milestone payments and royalties from the sale of any products developed from the partnership. Compugen also retains the exclusive right to drug applications of the targets and associated antibodies.

Compugen shares rose 14 cents, or 5.4 percent, to $2.74 in afternoon trading on the Nasdaq Stock Market, while Biosite shares edged up 7 cents to $53.89.

More information on Compugen Ltd. available in the members section of www.BellwetherReport.com.

To review research on Compugen Ltd. as well as many more exciting articles we encourage you to visit www.bellwetherreport.com. You can find these reports under the "Today's Articles" section. No credit Card Needed!!

The Bellwether Report will continue to research the small cap markets to bring you exciting opportunities!! If you are interested in receiving more information on these small cap opportunities and other features of our site, feel free to sign up for a complimentary subscription to the #1 online investment tool www.bellwetherreport.com.

Companies looking to advertise with Bellwether Report should email jlee@bellwetherreport.com with the subject line (Advertising).

Information has been gathered from sources such as www.Hoovers.com, www.yahoo.com, www.associatedpress.com, www.marketwire.com, www.businesswire.com and other public resources.




Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist